(Q35893387)

11 August 2017

1 reference

title

What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? (English)

1 reference

11 August 2017

1 reference

Dieter Schmidt

1

1 reference

PubMed ID

15380112

11 August 2017

Christian E Elger

series ordinal

2

1 reference

11 August 2017

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

627-635

1 reference

11 August 2017

5

1 reference

Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

The metabolism of 14C-oxcarbazepine in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Clinical pharmacology and pharmacokinetics of oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine: pharmacokinetic interactions and their clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Clinical pharmacokinetics of oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Thyroid and Myocardial Function After Replacement of Carbamazepine by Oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Dose dependent enzyme induction by oxcarbazepine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Serum sex hormone levels after replacing carbamazepine with oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Effect of epilepsy and antiepileptic drugs on male reproductive health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Comparison of oxcarbazepine and carbamazepine: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine: an update of its efficacy in the management of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

How is oxcarbazepine different from carbamazpine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

[Oxcarbazepine (Trileptal). An effective and well tolerated new drug as first choice in treatment of focal seizures]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Spotlight on oxcarbazepine in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Possible interaction between oxcarbazepine and an oral contraceptive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Cross-reactive skin eruption with both carbamazepine and oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine in pregnancy: clinical experience in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Major malformations in offspring of women with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Causes and Management of Hyponatremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

The regulation of serum sodium after replacing carbamazepine with oxcarbazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Effects of oxcarbazepine on sodium concentration and water handling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2004.07.004

10.1016/J.YEBEH.2004.07.004

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15380112